Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
Status:
Completed
Trial end date:
2021-06-05
Target enrollment:
Participant gender:
Summary
There is an urgent need for effective therapies against the novel COVID-19 virus. Studies
have shown that amiodarone and verapamil can interfere with coronavirus entry and
amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate
amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with
confirmed COVID-19 infection.